Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy

Exclusion Criteria

• •Patient with a diagnosis of hepatocellular carcinoma, decompensated cirrhosis, and/or liver transplantation prior to the development of drug resistance to NA therapy for CHB
• •Patient with co-infection with hepatitis C virus, hepatitis D virus, and/or human immunodeficiency virus
• •Patient with life expectancy less than 6 months after the date of the first laboratory test indicating drug resistance